BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207
3296 results:

  • 1. [Explore the mechanism of astragaloside IV-PESV on proliferation, migration, and autophagy of prostate cancer cells based on the PI3K/akt signaling pathway].
    You XJ; Wen Z; Zheng QX; Li QX; Fu W; Li HS; Wang B
    Zhonghua Nan Ke Xue; 2023 Dec; 29(12):963-972. PubMed ID: 38639947
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. [Mechanism study on the effect of androgen antagonism in prostate cancer].
    Song X; Song Q; Wang R; Zuo QJ; Zhang ZY
    Zhonghua Nan Ke Xue; 2023 May; 29(5):402-408. PubMed ID: 38602755
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Nutritional Sources and Anticancer Potential of Phenethyl Isothiocyanate: Molecular Mechanisms and Therapeutic Insights.
    M Ezzat S; M Merghany R; M Abdel Baki P; Ali Abdelrahim N; M Osman S; A Salem M; Peña-Corona SI; Cortés H; Kiyekbayeva L; Leyva-Gómez G; Sharifi-Rad J; Calina D
    Mol Nutr Food Res; 2024 Apr; 68(8):e2400063. PubMed ID: 38600885
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The protein composition of exosomes released by prostate cancer cells is distinctly regulated by androgen receptor-antagonists and -agonist to stimulate growth of target cells.
    Atri Roozbahani G; Kokal-Ribaudo M; Heidari Horestani M; Pungsrinont T; Baniahmad A
    Cell Commun Signal; 2024 Apr; 22(1):219. PubMed ID: 38589887
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Unveiling the Anticancer Potential of Pasak Bumi (Eurycoma Longifolia Jack) Root Extract in prostate cancer Treatment.
    Rahman EY; Kania N; Sutapa H; Purnomo AF; Panghiyangani R; Skripsiana NS
    Med Arch; 2024; 78(2):117-121. PubMed ID: 38566865
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.
    Fonseca-Alves CE; Leis-Filho AF; Lacerda ZA; de Faria Lainetti P; Amorim RL; Rogatto SR
    PLoS One; 2024; 19(4):e0297043. PubMed ID: 38564578
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. The interplay between autophagy and ferroptosis presents a novel conceptual therapeutic framework for neuroendocrine prostate cancer.
    Wang Y; Wu N; Li J; Liang J; Zhou D; Cao Q; Li X; Jiang N
    Pharmacol Res; 2024 May; 203():107162. PubMed ID: 38554788
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Decision regret of cancer patients after radiotherapy: results from a cross-sectional observational study at a large tertiary cancer center in Germany.
    Rühle A; Wieland L; Hinz A; Mehnert-Theuerkauf A; Nicolay NH; Seidel C
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):167. PubMed ID: 38546873
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Microbiome Dysbiosis Is Associated with Castration Resistance and cancer Stemness in Metastatic prostate cancer.
    Uzelac M; Xin R; Ongkeko WM
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542265
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Tyrosine phosphatase
    Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
    Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. CPT1A mediates the succinylation of SP5 which activates transcription of PDPK1 to promote the viability and glycolysis of prostate cancer cells.
    Liu S; Chen X; Zhang L; Lu B
    Cancer Biol Ther; 2024 Dec; 25(1):2329372. PubMed ID: 38494680
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Network pharmacology and experimental evaluation strategies to decipher the underlying pharmacological mechanism of Traditional Chinese Medicine CFF-1 against prostate cancer.
    Wei Y; Zhu M; Chen Y; Ji Q; Wang J; Shen L; Yang X; Hu H; Zhou X; Zhu Q
    Aging (Albany NY); 2024 Mar; 16(6):5387-5411. PubMed ID: 38484140
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Multifaceted impact of adipose conditioned media: Obesity-driven promotion of prostate cancer and cancer stem cell dynamics.
    Erdogan S; Serttas R; Dibirdik I; Turkekul K
    Cell Biochem Funct; 2024 Mar; 42(2):e3979. PubMed ID: 38481004
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Flubendazole suppresses VEGF-induced angiogenesis in HUVECs and exerts antitumor effects in PC-3 cells.
    Zhang B; Zhao J; Kang D; Wang Z; Xu L; Zheng R; Liu A
    Chem Biol Drug Des; 2024 Mar; 103(3):e14503. PubMed ID: 38480495
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of akt-mediated survival mechanisms in prostate cancer.
    Eberlein C; Williamson SC; Hopcroft L; Ros S; Moss JI; Kerr J; van Weerden WM; de Bruin EC; Dunn S; Willis B; Ross SJ; Rooney C; Barry ST
    Br J Cancer; 2024 May; 130(8):1377-1387. PubMed ID: 38396173
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Capivasertib: First Approval.
    Shirley M
    Drugs; 2024 Mar; 84(3):337-346. PubMed ID: 38388873
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trial.
    Smith TAD; West CML; Joseph N; Lane B; Irlam-Jones J; More E; Mistry H; Reeves KJ; Song YP; Reardon M; Hoskin PJ; Hussain SA; Denley H; Hall E; Porta N; Huddart RA; James ND; Choudhury A
    EBioMedicine; 2024 Mar; 101():105032. PubMed ID: 38387404
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation.
    Ashrafizadeh M; Zhang W; Tian Y; Sethi G; Zhang X; Qiu A
    Cancer Metastasis Rev; 2024 Mar; 43(1):229-260. PubMed ID: 38374496
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Food additive emulsifiers and cancer risk: Results from the French prospective NutriNet-Santé cohort.
    Sellem L; Srour B; Javaux G; Chazelas E; Chassaing B; Viennois E; Debras C; Druesne-Pecollo N; Esseddik Y; Szabo de Edelenyi F; Arnault N; Agaësse C; De Sa A; Lutchia R; Huybrechts I; Scalbert A; Pierre F; Coumoul X; Julia C; Kesse-Guyot E; Allès B; Galan P; Hercberg S; Deschasaux-Tanguy M; Touvier M
    PLoS Med; 2024 Feb; 21(2):e1004338. PubMed ID: 38349899
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Development of certain benzylidene coumarin derivatives as anti-prostate cancer agents targeting EGFR and PI3Kβ kinases.
    Elagawany M; Abdel Ghany LMA; Ibrahim TS; Alharbi AS; Abdel-Aziz MS; El-Labbad EM; Ryad N
    J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2311157. PubMed ID: 38348846
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 165.